English
Arabic
Chinese (Simplified)
French
German
Greek
Italian
Japanese
Portuguese
Spanish
CUREVAC AND BAYER JOIN FORCES ON COVID-19 VACCINE CANDIDATE CVNCOV
CUREVAC
Bayer has signed a collaboration and services agreement with CureVac N.V., a biopharmaceutical company developing a new class of life-changing medicines based on messenger ribonucleic acid (mRNA).
Under the terms of the agreement, Bayer will support the further development, supply, and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. In addition, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance. CureVac will serve as the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union and selected additional markets.
WHY IT MATTERS: With COVID-19 cases and deaths rising exponentially, this partnership aims to play a meaningful role in bringing an end to today’s pandemic. Leveraging their unique strengths, the companies are working together to enable CureVac to supply hundreds of millions of CVnCoV doses around the world, once approvals are granted.
CLIO PARTNERS WITH THE BLACK PROFESSIONALS IN TECH NETWORK (BPTN) TO ENACT POSITIVE SOCIAL CHANGE IN THE TECH COMMUNITY
CLIO
Clio, the leader in cloud-based legal technology, announces a new partnership with the Black Professionals in Tech Network (BPTN), an organization advancing opportunities for Black technical and business professionals in order to bridge the tech industry’s talent gap.
Together, Clio and BPTN will engage in an ongoing process of learning, discussion, and support, with a mutual commitment to fostering a more diverse, inclusive, and equitable future in tech. Clio is striving to become an anti-racist organization and is actively working to identify and oppose unconscious biases and change the behaviors, beliefs, and systemic issues that perpetuate racist ideas, actions, and practices. To support these efforts, Clio is prioritizing company initiatives that drive Diversity, Inclusion, Belonging, and Equity (DIBE), and tracking progress towards achieving this goal. BPTN’s mission and approach align with the transformation Clio aims to accomplish, both internally and within the industry. This partnership will include a variety of culture and learning sessions hosted by BPTN to provide insight into the Black tech ecosystem and equip employees with actionable takeaways to create and maintain a more diverse and inclusive company culture. These sessions will help Clio build corporate solutions that are practical, sustainable, scalable, and aligned with its larger strategic goals and long-held commitment to DIBE.
WHY IT MATTERS: Through this partnership, Clio will provide Black developers, engineers, sales, and marketing professionals with access to senior executive sponsorship, industry training, and a strong peer network to support their growth and development. BPTN will help technology companies hire and promote Black tech talent through pipeline building and internal culture development.
NEW PARTNERSHIP ANNOUNCED BETWEEN THE UNIVERSITY OF BIRMINGHAM AND MED-TECH COMPANY APARITO
UNIVERSITY OF BIRMINGHAM
The University of Birmingham in the UK has announced a partnership with med-tech company Aparito to co-develop digital platforms to assess patient quality of life and symptoms in clinical trials and routine National Health Service (NHS) care.
This partnership will see the configuration of Aparito’s flagship software platform Atom5™, and brings together international experts in patient-reported outcomes (PROs) methodology, patients, and clinicians, using cutting-edge technology. The collective data will support patient care and provide evidence to inform regulators and policy makers such as the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).
WHY IT MATTERS: The aim of the partnership is to co-develop multiple digital PROs for use in a wide range of disease groups to assess treatment safety and effectiveness from the patient perspective and enhance the patient experience of clinical trials and routine care.